Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts
Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growt...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2014-08, Vol.20 (31), p.10769-10777 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10777 |
|---|---|
| container_issue | 31 |
| container_start_page | 10769 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 20 |
| creator | Kruger, Stephan Haas, Michael Ormanns, Steffen Bächmann, Sibylle Siveke, Jens T Kirchner, Thomas Heinemann, Volker Boeck, Stefan |
| description | Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy. |
| doi_str_mv | 10.3748/wjg.v20.i31.10769 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4138457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>90888889504849525149484950</cqvip_id><sourcerecordid>1609308016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-187b71a16bf703f6826d6d72c2b51424805831305c11354ad3a6c55a343e3ae73</originalsourceid><addsrcrecordid>eNpVkUFvEzEQhS0EomnhB3BBe-SyYcZj73o5IKGqLUiVeiln43i9iauNndq7Qfx7nDZEdC4e-b15M9LH2AeEJbVCff79sF7uOSw94RKhbbpXbME5djVXAl6zBQK0dUe8PWPnOT8AcCLJ37IzLlFyqWDBft0nE_JoJh-DGavksjPJbiofqp0JNrmi2Kqf7VRU07sQbdF9iFvzpbJzSi5Mldv7olhXmdBXwzzNyVU2lo_dlN-xN4MZs3t_fC_Yz-ur-8vv9e3dzY_Lb7e1FYKmGlW7atFgsxpaoKFRvOmbvuWWryQKLhRIRUggLSJJYXoyjZXSkCBHxrV0wb4-5-7m1db1ttyVzKh3yW9N-qOj8fqlEvxGr-NeCyQl5CHg0zEgxcfZ5UlvfbZuHE1wcc4aG-gIFGBTrPhstSnmnNxwWoOgD2R0IaMLGV3I6CcyZebj__edJv6hKAY6hm5iWD_6sD55OlCH6iQIJbpiR9E9dUB_AR5Nm9o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1609308016</pqid></control><display><type>article</type><title>Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kruger, Stephan ; Haas, Michael ; Ormanns, Steffen ; Bächmann, Sibylle ; Siveke, Jens T ; Kirchner, Thomas ; Heinemann, Volker ; Boeck, Stefan</creator><creatorcontrib>Kruger, Stephan ; Haas, Michael ; Ormanns, Steffen ; Bächmann, Sibylle ; Siveke, Jens T ; Kirchner, Thomas ; Heinemann, Volker ; Boeck, Stefan</creatorcontrib><description>Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v20.i31.10769</identifier><identifier>PMID: 25152580</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarker ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - genetics ; Carcinoma, Pancreatic Ductal - metabolism ; Carcinoma, Pancreatic Ductal - pathology ; equilibrativ ; Erlotinib ; Gemcitabine ; Human ; Humans ; Molecular Targeted Therapy ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Precision Medicine ; Predictive Value of Tests ; Signal Transduction ; Topic Highlight ; Translational Research, Biomedical</subject><ispartof>World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10769-10777</ispartof><rights>2014 Baishideng Publishing Group Inc. All rights reserved. 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-187b71a16bf703f6826d6d72c2b51424805831305c11354ad3a6c55a343e3ae73</citedby><cites>FETCH-LOGICAL-c443t-187b71a16bf703f6826d6d72c2b51424805831305c11354ad3a6c55a343e3ae73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138457/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138457/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25152580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kruger, Stephan</creatorcontrib><creatorcontrib>Haas, Michael</creatorcontrib><creatorcontrib>Ormanns, Steffen</creatorcontrib><creatorcontrib>Bächmann, Sibylle</creatorcontrib><creatorcontrib>Siveke, Jens T</creatorcontrib><creatorcontrib>Kirchner, Thomas</creatorcontrib><creatorcontrib>Heinemann, Volker</creatorcontrib><creatorcontrib>Boeck, Stefan</creatorcontrib><title>Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarker</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - genetics</subject><subject>Carcinoma, Pancreatic Ductal - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>equilibrativ</subject><subject>Erlotinib</subject><subject>Gemcitabine</subject><subject>Human</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Precision Medicine</subject><subject>Predictive Value of Tests</subject><subject>Signal Transduction</subject><subject>Topic Highlight</subject><subject>Translational Research, Biomedical</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUFvEzEQhS0EomnhB3BBe-SyYcZj73o5IKGqLUiVeiln43i9iauNndq7Qfx7nDZEdC4e-b15M9LH2AeEJbVCff79sF7uOSw94RKhbbpXbME5djVXAl6zBQK0dUe8PWPnOT8AcCLJ37IzLlFyqWDBft0nE_JoJh-DGavksjPJbiofqp0JNrmi2Kqf7VRU07sQbdF9iFvzpbJzSi5Mldv7olhXmdBXwzzNyVU2lo_dlN-xN4MZs3t_fC_Yz-ur-8vv9e3dzY_Lb7e1FYKmGlW7atFgsxpaoKFRvOmbvuWWryQKLhRIRUggLSJJYXoyjZXSkCBHxrV0wb4-5-7m1db1ttyVzKh3yW9N-qOj8fqlEvxGr-NeCyQl5CHg0zEgxcfZ5UlvfbZuHE1wcc4aG-gIFGBTrPhstSnmnNxwWoOgD2R0IaMLGV3I6CcyZebj__edJv6hKAY6hm5iWD_6sD55OlCH6iQIJbpiR9E9dUB_AR5Nm9o</recordid><startdate>20140821</startdate><enddate>20140821</enddate><creator>Kruger, Stephan</creator><creator>Haas, Michael</creator><creator>Ormanns, Steffen</creator><creator>Bächmann, Sibylle</creator><creator>Siveke, Jens T</creator><creator>Kirchner, Thomas</creator><creator>Heinemann, Volker</creator><creator>Boeck, Stefan</creator><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140821</creationdate><title>Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts</title><author>Kruger, Stephan ; Haas, Michael ; Ormanns, Steffen ; Bächmann, Sibylle ; Siveke, Jens T ; Kirchner, Thomas ; Heinemann, Volker ; Boeck, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-187b71a16bf703f6826d6d72c2b51424805831305c11354ad3a6c55a343e3ae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarker</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - genetics</topic><topic>Carcinoma, Pancreatic Ductal - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>equilibrativ</topic><topic>Erlotinib</topic><topic>Gemcitabine</topic><topic>Human</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Precision Medicine</topic><topic>Predictive Value of Tests</topic><topic>Signal Transduction</topic><topic>Topic Highlight</topic><topic>Translational Research, Biomedical</topic><toplevel>online_resources</toplevel><creatorcontrib>Kruger, Stephan</creatorcontrib><creatorcontrib>Haas, Michael</creatorcontrib><creatorcontrib>Ormanns, Steffen</creatorcontrib><creatorcontrib>Bächmann, Sibylle</creatorcontrib><creatorcontrib>Siveke, Jens T</creatorcontrib><creatorcontrib>Kirchner, Thomas</creatorcontrib><creatorcontrib>Heinemann, Volker</creatorcontrib><creatorcontrib>Boeck, Stefan</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kruger, Stephan</au><au>Haas, Michael</au><au>Ormanns, Steffen</au><au>Bächmann, Sibylle</au><au>Siveke, Jens T</au><au>Kirchner, Thomas</au><au>Heinemann, Volker</au><au>Boeck, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2014-08-21</date><risdate>2014</risdate><volume>20</volume><issue>31</issue><spage>10769</spage><epage>10777</epage><pages>10769-10777</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>25152580</pmid><doi>10.3748/wjg.v20.i31.10769</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10769-10777 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4138457 |
| source | MEDLINE; Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarker Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology equilibrativ Erlotinib Gemcitabine Human Humans Molecular Targeted Therapy Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Precision Medicine Predictive Value of Tests Signal Transduction Topic Highlight Translational Research, Biomedical |
| title | Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T15%3A37%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translational%20research%20in%20pancreatic%20ductal%20adenocarcinoma:%20current%20evidence%20and%20future%20concepts&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Kruger,%20Stephan&rft.date=2014-08-21&rft.volume=20&rft.issue=31&rft.spage=10769&rft.epage=10777&rft.pages=10769-10777&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v20.i31.10769&rft_dat=%3Cproquest_pubme%3E1609308016%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1609308016&rft_id=info:pmid/25152580&rft_cqvip_id=90888889504849525149484950&rfr_iscdi=true |